106.90
Lemaitre Vascular Inc stock is traded at $106.90, with a volume of 71,079.
It is down -1.04% in the last 24 hours and up +22.97% over the past month.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.
See More
Previous Close:
$107.85
Open:
$107.43
24h Volume:
71,079
Relative Volume:
0.40
Market Cap:
$2.42B
Revenue:
$240.87M
Net Income/Loss:
$53.34M
P/E Ratio:
46.00
EPS:
2.3238
Net Cash Flow:
$66.23M
1W Performance:
+16.79%
1M Performance:
+22.97%
6M Performance:
+9.95%
1Y Performance:
+17.97%
Lemaitre Vascular Inc Stock (LMAT) Company Profile
Name
Lemaitre Vascular Inc
Sector
Industry
Phone
781-221-2266
Address
63 SECOND AVENUE, BURLINGTON, MA
Compare LMAT vs ISRG, BDX, ALC, RMD, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
LMAT
Lemaitre Vascular Inc
|
106.72 | 2.45B | 240.87M | 53.34M | 66.23M | 2.3238 |
|
ISRG
Intuitive Surgical Inc
|
501.94 | 176.65B | 10.06B | 2.88B | 2.49B | 7.876 |
|
BDX
Becton Dickinson Co
|
171.29 | 49.56B | 21.92B | 1.76B | 2.63B | 6.1223 |
|
ALC
Alcon Inc
|
83.98 | 40.50B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
RMD
Resmed Inc
|
258.91 | 37.63B | 5.40B | 1.49B | 1.78B | 10.12 |
|
MDLN
Medline Inc
|
43.16 | 36.02B | 28.43B | 1.16B | 1.26B | 1.4457 |
Lemaitre Vascular Inc Stock (LMAT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-28-25 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Feb-28-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-13-25 | Initiated | Wells Fargo | Equal Weight |
| Oct-15-24 | Initiated | Cantor Fitzgerald | Neutral |
| Aug-02-24 | Resumed | Lake Street | Buy |
| May-31-24 | Resumed | ROTH MKM | Buy |
| Apr-26-24 | Upgrade | Stifel | Hold → Buy |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Sector Weight |
| Oct-23-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-06-23 | Initiated | Oppenheimer | Outperform |
| Aug-03-23 | Downgrade | Jefferies | Buy → Hold |
| May-03-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-28-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-16-21 | Initiated | Jefferies | Buy |
| Feb-12-21 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Mar-16-20 | Upgrade | Sidoti | Neutral → Buy |
| Oct-24-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Oct-24-19 | Upgrade | Lake Street | Hold → Buy |
| Oct-14-19 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Jul-25-19 | Reiterated | Barrington Research | Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| Oct-08-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-08-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Jun-08-18 | Resumed | ROTH Capital | Buy |
| Apr-26-18 | Downgrade | Stifel | Buy → Hold |
| Apr-26-18 | Upgrade | The Benchmark Company | Hold → Buy |
| Oct-27-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Oct-27-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Jul-10-17 | Downgrade | Canaccord Genuity | Buy → Hold |
| Jul-10-17 | Downgrade | The Benchmark Company | Buy → Hold |
| Mar-21-17 | Initiated | First Analysis Sec | Overweight |
| Feb-22-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Sep-22-16 | Downgrade | Sidoti | Buy → Neutral |
| Jul-28-16 | Reiterated | Barrington Research | Outperform |
| Feb-25-16 | Reiterated | Barrington Research | Outperform |
View All
Lemaitre Vascular Inc Stock (LMAT) Latest News
LeMaitre Vascular Hits Day High with 24.41% Surge in Stock Price - Markets Mojo
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Average Rating of "Hold" from Analysts - MarketBeat
LeMaitre Vascular Experiences Revision in Its Stock Evaluation Amid Competitive Market Dynamics - Markets Mojo
LeMaitre Vascular Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
LeMaitre Vascular Hits New 52-Week High at $115.33, Up 46.41% - Markets Mojo
LeMaitre Vascular Stock Forms Golden Cross, Signals Bullish Breakout Ahead - Markets Mojo
LMAT SEC FilingsLemaitre Vasculr 10-K, 10-Q, 8-K Forms - Stock Titan
LeMaitre Vascular, Inc. (LMAT) Stock Analysis: Strong Buy Ratings Amid Steady Revenue Growth - DirectorsTalk Interviews
LeMaitre (LMAT) director Roush gains 476 shares from PSU vesting - Stock Titan
Lemaitre Vascular SVP Kamke sells $115k in LMAT stock By Investing.com - Investing.com India
LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $6,029,813.30 in Stock - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Director Sells $903,955.20 in Stock - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) CEO Sells $16,014,000.00 in Stock - MarketBeat
LeMaitre Vascular (NASDAQ:LMAT) Insider Sells $115,142.76 in Stock - MarketBeat
Lemaitre Vascular SVP Kamke sells $115k in LMAT stock - Investing.com
LeMaitre Vascular (LMAT) president reports sale of 8,464 shares - Stock Titan
LeMaitre Vascular (LMAT) director gains stock through PSU vesting and dividend rights - Stock Titan
LMAT (LMAT) CEO LeMaitre reports 205,930-share sale, PSU vesting and gift - Stock Titan
George W. LeMaitre sells 150,000 shares (LMAT) in Form 144 - Stock Titan
LeMaitre Vascular (LMAT)'s Technical Outlook is Bright After Key Golden Cross - sharewise.com
LeMaitre Vascular (LMAT) Is Up 16.4% After Dividend Hike And Buyback Plan – Has The Bull Case Changed? - Yahoo Finance
LeMaitre Vascular (LMAT) Shows Promising Technical Prospects Following Significant Golden Cross - Bitget
How The LeMaitre Vascular (LMAT) Investment Story Is Evolving With New Targets And Guidance - Yahoo Finance
LeMaitre Vascular Signals Confident Growth in Earnings Call - The Globe and Mail
LeMaitre Vascular, Inc. (LMAT): A Bull Case Theory - Yahoo Finance
LMAT: Morgan Stanley Smith Barney files Form 144 for vested restricted shares (LMAT) - Stock Titan
LeMaitre Vascular: The Compounder Keeps Compounding (NYSE:MDT) - Seeking Alpha
LeMaitre to Participate at Upcoming Investor Conferences in March - marketscreener.com
Five investor conferences spotlight LeMaitre in busy March - Stock Titan
[144] LEMAITRE VASCULAR INC SEC Filing - Stock Titan
LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q4 2025 Earnings Call Transcript - Insider Monkey
LeMaitre Vascular Stock Surges 24% After Q4 Sales Beat. Is the $104 Street Target Still in Play? - TIKR.com
LeMaitre Vascular Q4 2025 Earnings: Revenue & Profit Exceed ExpectationsNews and Statistics - IndexBox
LeMaitre Vascular stock reaches 52-week high at 103.05 USD By Investing.com - Investing.com Australia
LeMaitre Vascular (LMAT) Gets Price Target Boost from Barrington Research | LMAT Stock News - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Price Target Raised to $105.00 - MarketBeat
LeMaitre Vascular Q4 2025 Earnings Beat, Provides Strong 2026 OutlookNews and Statistics - IndexBox
LeMaitre Sees Growth Surge with Promising Earnings, Revenue Outlook - StocksToTrade
Roth Mkm Reaffirms Buy Rating for LeMaitre Vascular (NASDAQ:LMAT) - MarketBeat
Breaking Down LeMaitre Vascular: 4 Analysts Share Their Views - Benzinga
LeMaitre Vascular Shares Rise After Barrington Price Target Boost, Q4 Results - marketscreener.com
LeMaitre (LMAT) Stock Trades Up, Here Is Why - Finviz
LMAT Price Target Raised by Wells Fargo | LMAT Stock News - GuruFocus
Wells Fargo & Company Issues Positive Forecast for LeMaitre Vascular (NASDAQ:LMAT) Stock Price - MarketBeat
LMAT: Citizens Raises Price Target to $118, Maintains Market Out - GuruFocus
LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High After Strong Earnings - MarketBeat
Barrington Adjusts Price Target on LeMaitre Vascular to $105 From $95, Maintains Outperform Rating - marketscreener.com
LeMaitre Vascular (NASDAQ:LMAT) Stock Price Expected to Rise, Citizens Jmp Analyst Says - MarketBeat
LeMaitre Vascular stock reaches 52-week high at 103.05 USD - Investing.com
Income Plays: Is LeMaitre Vascular Inc stock a value trapJuly 2025 Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
LEMAITRE VASCULAR INC SEC 10-K Report - TradingView
Lemaitre Vascular Inc Stock (LMAT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):